Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))

Alexander B. Olawaiye; James J. Java; Thomas C. Krivak; Michael Friedlander; David G. Mutch; Gretchen Glaser; Melissa Geller; David M. O'Malley; Robert M. Wenham; Roger B. Lee; Diane C. Bodurka; Thomas J. Herzog; Michael A. Bookman

doi:10.1016/j.ygyno.2018.10.022

Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))

Alexander B. Olawaiye
, James J. Java
, Thomas C. Krivak
, Michael Friedlander
, David G. Mutch
, Gretchen Glaser
, Melissa Geller
, David M. O'Malley
, Robert M. Wenham
, Roger B. Lee
, Diane C. Bodurka
, Thomas J. Herzog
, Michael A. Bookman

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below: Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.

Original language	English (US)
Pages (from-to)	220
Number of pages	1
Journal	Gynecologic oncology
Volume	152
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2018.10.022
State	Published - Jan 2019

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

PubMed: MeSH publication types

Published Erratum
Journal Article

Publisher link

10.1016/j.ygyno.2018.10.022

Find It

Find It at U of M Libraries

Fingerprint

Dive into the research topics of 'Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))'. Together they form a unique fingerprint.

Cite this

Olawaiye, A. B., Java, J. J., Krivak, T. C., Friedlander, M., Mutch, D. G., Glaser, G., Geller, M., O'Malley, D. M., Wenham, R. M., Lee, R. B., Bodurka, D. C., Herzog, T. J., & Bookman, M. A. (2019). Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021)). Gynecologic oncology, 152(1), 220. https://doi.org/10.1016/j.ygyno.2018.10.022

Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021)). / Olawaiye, Alexander B.; Java, James J.; Krivak, Thomas C. et al.
In: Gynecologic oncology, Vol. 152, No. 1, 01.2019, p. 220.

Research output: Contribution to journal › Comment/debate › peer-review

Olawaiye, AB, Java, JJ, Krivak, TC, Friedlander, M, Mutch, DG, Glaser, G, Geller, M, O'Malley, DM, Wenham, RM, Lee, RB, Bodurka, DC, Herzog, TJ & Bookman, MA 2019, 'Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))', Gynecologic oncology, vol. 152, no. 1, pp. 220. https://doi.org/10.1016/j.ygyno.2018.10.022

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G et al. Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021)). Gynecologic oncology. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022

Olawaiye, Alexander B. ; Java, James J. ; Krivak, Thomas C. et al. / Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021)). In: Gynecologic oncology. 2019 ; Vol. 152, No. 1. pp. 220.

@article{d82ea273ca774516bbabdd2ef0ef3124,

title = "Corrigendum to {\textquotedblleft}Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study{\textquotedblright} (Gynecologic Oncology (2018) 151(1) (18{\textendash}23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))",

abstract = "The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below: Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.",

author = "Olawaiye, \{Alexander B.\} and Java, \{James J.\} and Krivak, \{Thomas C.\} and Michael Friedlander and Mutch, \{David G.\} and Gretchen Glaser and Melissa Geller and O'Malley, \{David M.\} and Wenham, \{Robert M.\} and Lee, \{Roger B.\} and Bodurka, \{Diane C.\} and Herzog, \{Thomas J.\} and Bookman, \{Michael A.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = jan,

doi = "10.1016/j.ygyno.2018.10.022",

language = "English (US)",

volume = "152",

pages = "220",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))

AU - Olawaiye, Alexander B.

AU - Java, James J.

AU - Krivak, Thomas C.

AU - Friedlander, Michael

AU - Mutch, David G.

AU - Glaser, Gretchen

AU - Geller, Melissa

AU - O'Malley, David M.

AU - Wenham, Robert M.

AU - Lee, Roger B.

AU - Bodurka, Diane C.

AU - Herzog, Thomas J.

AU - Bookman, Michael A.

PY - 2019/1

Y1 - 2019/1

N2 - The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below: Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below: Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85055083698

UR - https://www.scopus.com/pages/publications/85055083698#tab=citedBy

U2 - 10.1016/j.ygyno.2018.10.022

DO - 10.1016/j.ygyno.2018.10.022

M3 - Comment/debate

C2 - 30360899

AN - SCOPUS:85055083698

SN - 0090-8258

VL - 152

SP - 220

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 1

ER -